Despite the initial success at prolonging survival rates compared to prior standards therapies, available follow-up data with FLT3 inhibitor therapies show that this class of drug is plagued by short duration of response and nearly inevitable relapse when given combined with other AML therapies [7, 10]. Here, FLT3 is linked to acute myeloid leukemia.